Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
The Oncologist
|
June 16, 2021
FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Yvette L Kasamon, Lauren S L Price, Olanrewaju O Okusanya, et al.
The Oncologist
|
December 21, 2020
Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy
Lorraine Pelosof, May Tun Saung, Martha Donoghue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2019
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
V Ellen Maher, Laura L Fernandes, Chana Weinstock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2019
Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis
Lynn J Howie, Harpreet Singh, Erik Bloomquist, et al.
The Oncologist
|
July 6, 2024
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations
Gautam U Mehta, Paz J Vellanki, Yi Ren, et al.
Cytotherapy
|
February 27, 2022
Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials
Mark D Stewart, Bruce McCall, Marcelo Pasquini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 24, 2025
US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia
Nina Kim, E Dianne Pulte, Lori A Ehrlich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 7, 2014
FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation
Geoffrey Kim, Amy E McKee, Yang-Min Ning, et al.
Clinical Pharmacology and Therapeutics
|
June 5, 2025
Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs
Wei Gao, Jiang Liu, Cynthia J Musante, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 11, 2021
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice
David J Pinato, Thomas U Marron, Pallavi Shruti Mishra-Kalyani, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
The Oncologist
|
June 16, 2021
FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Yvette L Kasamon, Lauren S L Price, Olanrewaju O Okusanya, et al.
The Oncologist
|
December 21, 2020
Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy
Lorraine Pelosof, May Tun Saung, Martha Donoghue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2019
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
V Ellen Maher, Laura L Fernandes, Chana Weinstock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2019
Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis
Lynn J Howie, Harpreet Singh, Erik Bloomquist, et al.
The Oncologist
|
July 6, 2024
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations
Gautam U Mehta, Paz J Vellanki, Yi Ren, et al.
Cytotherapy
|
February 27, 2022
Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials
Mark D Stewart, Bruce McCall, Marcelo Pasquini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 24, 2025
US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia
Nina Kim, E Dianne Pulte, Lori A Ehrlich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 7, 2014
FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation
Geoffrey Kim, Amy E McKee, Yang-Min Ning, et al.
Clinical Pharmacology and Therapeutics
|
June 5, 2025
Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs
Wei Gao, Jiang Liu, Cynthia J Musante, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 11, 2021
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice
David J Pinato, Thomas U Marron, Pallavi Shruti Mishra-Kalyani, et al.
Page
of 2